An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology Symposium
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Glaukos Corporation (NYSE: GKOS) announced its virtual participation in the Piper Sandler Ophthalmology Symposium on May 23, 2022, at 2:00 p.m. ET. The company is focused on innovative therapies for glaucoma, corneal disorders, and retinal diseases. Glaukos pioneered Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to traditional treatments, launching its first MIGS device in 2012. The event will feature a live and archived webcast accessible through the Glaukos Investors section.
Positive
Participation in the Piper Sandler Ophthalmology Symposium enhances visibility in the ophthalmology sector.
Glaukos has a strong historical focus on innovation with its MIGS platform, supporting long-term growth potential.
Negative
None.
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the Piper Sandler Ophthalmology Symposium on Monday, May 23, 2022, at 2:00 p.m. ET.
A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and has since developed a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.
